Sanofi’s BTK inhibitor tolebrutinib shows ‘promising’ long-term MS data
Tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by MRI
Read More
Tag: BTK inhibitor
AZ’ Calquence shows promise for COVID-19
Improved markers of inflammation and reduced oxygen requirements were seen in most patients
Read More
AZ to test Calquence for COVID-19
The moves follows ‘strong scientific evidence’ indicating the role of the BTK pathway in the production of inflammatory cytokines
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
